Table 2.
Cox proportional hazard regression analysis of factors associated with progression-free survival.
| Variables | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | |
| Age | 0.990 (0.945–1.037) | 0.664 | ||
| BMI | 1.007 (0.893–1.136) | 0.904 | ||
| PSA | 1.003 (1.000–1.005) | 0.024 | 1.002 (1.000–1.004) | 0.03 |
| CCI | 0.476 | |||
| ≤1 | 1 (Ref) | |||
| ≥2 | 1.291 (0.640–2.602) | |||
| Biopsy GG | 0.002 | 0.002 | ||
| ≤4 | 1 (Ref) | 1 (Ref) | ||
| 5 | 2.535 (1.404–4.575) | 2.504 (1.384–4.531) | ||
| Clinical T stage | 0.239 | |||
| ≤T3 | 1 (Ref) | |||
| T4 | 1.500 (0.764–2.945) | |||
| Clinical N stage | 0.092 | |||
| N0 | 1 (Ref) | |||
| N1 | 1.635 (0.923–2.896) | |||
| Clinical M stage | 0.587 | |||
| M1a | 1 (Ref) | |||
| M1b | 1.330 (0.475–3.722) | |||
| Pelvic LN treatment | 1.330 (0.642–2.755) | 0.443 | ||
| Type of local therapy | 0.356 | |||
| RP | 1 (Ref) | |||
| RT | 1.334 (0.724–2.459) | |||
HR, hazard ratio; CI, confidence interval; BMI, body mass index; PSA, prostate-specific antigen; CCI, Charlson comorbidity index; GG, Gleason grade; RP, radical prostatectomy; RT, radiotherapy; LN, lymph node.